PlainRecalls
FDA Drug Moderate Class II Ongoing

Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle (NDC 68462-162-01), b.) 500-count bottle (NDC 68462-162-05), Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430.

Reported: June 4, 2025 Initiated: February 28, 2025 #D-0448-2025

Product Description

Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle (NDC 68462-162-01), b.) 500-count bottle (NDC 68462-162-05), Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430.

Reason for Recall

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Details

Units Affected
[100 Tablet Bottles] 59,952 bottles; [500 Tablet Bottles] 155,976 bottles
Distribution
U.S. Nationwide
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle (NDC 68462-162-01), b.) 500-count bottle (NDC 68462-162-05), Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430.. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: [100 Tablet Bottles] 59,952 bottles; [500 Tablet Bottles] 155,976 bottles.
Why was this product recalled?
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Which agency issued this recall?
This recall was issued by the FDA Drug on June 4, 2025. Severity: Moderate. Recall number: D-0448-2025.